Arvinas/ US04335A1051 /
2024-05-15 9:59:55 PM | Chg. +0.98 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
32.31USD | +3.13% | 31,170 Turnover: 1.03 mill. |
-Bid Size: - | -Ask Size: - | 33.84 | 32.18 |
GlobeNewswire
05-09
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
GlobeNewswire
05-07
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
02-27
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
02-20
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for ...
GlobeNewswire
02-14
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focu...
GlobeNewswire
02-14
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in C...
GlobeNewswire
02-06
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment o...
GlobeNewswire
2023-12-15
Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Com...
GlobeNewswire
2023-12-06
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 202...
GlobeNewswire
2023-12-05
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Pa...
GlobeNewswire
2023-11-28
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Ant...
GlobeNewswire
2023-11-13
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-11-07
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update